Glomerular disorder

This study looks at the long-term safety of a drug called iptacopan for adults with a kidney disease called primary IgA nephropathy. Participants have already completed earlier studies and will continue taking the drug to monitor side effects and see if it helps slow kidney damag…

This phase 2 trial tests whether dapagliflozin, a drug already used for diabetes and chronic kidney disease, can slow kidney damage in people with lupus nephritis. Lupus nephritis is a serious complication of lupus that causes kidney inflammation and can lead to chronic kidney di…

This study tests a drug called sparsentan for people who have protein in their urine after a kidney transplant due to IgA nephropathy or FSGS. About 20 adults will take the drug once daily for 36 weeks to see if it safely reduces protein levels and protects kidney function. The g…

This study will follow 50 people with C3 glomerulopathy, a rare kidney disease, who are taking the drug Fabhalta. Researchers want to see how safe the drug is and how well it works in everyday clinical settings. They will track infections, side effects, and kidney function over t…

This phase 2 trial tests whether adding the oral drug iptacopan to standard therapy (rituximab) helps people with active ANCA vasculitis achieve and maintain remission. About 84 adults with newly diagnosed or relapsed disease will receive either iptacopan or a placebo, plus stand…

This phase 3 trial tests whether a new drug, depemokimab, works as well as the current treatment mepolizumab for adults with a rare disease called EGPA, which causes inflammation of blood vessels. The study involves 163 participants and aims to see if depemokimab can help patient…

This early-phase study tests a new treatment called NKX019 for people with lupus, an autoimmune disease. NKX019 uses specially engineered immune cells to target and calm overactive B cells. The main goal is to check safety in about 6 participants, while also looking for signs tha…

This study tests an experimental drug called APL2 for people with a kidney disease called FSGS. The goal is to see if APL2 can reduce protein in the urine, a sign of kidney damage. The trial has two parts: first, adults will receive APL2 openly; then, both adults and adolescents …

This phase 3 trial tests ravulizumab, a drug that blocks part of the immune system, against a placebo in 579 adults with IgA nephropathy—a kidney disease that can lead to kidney failure. The goal is to see if ravulizumab reduces protein in the urine and preserves kidney function …

This study looks at the long-term safety and effects of atacicept in people with IgA nephropathy, a kidney disease. Participants have already completed a previous trial with atacicept. Researchers will monitor side effects and measure kidney function over time to see if the drug …

This study tests a new treatment called CHT105 for people with lupus nephritis that hasn't responded to standard therapies. CHT105 uses specially engineered immune cells from healthy donors to target and destroy the faulty immune cells causing kidney damage. Fourteen adults will …

This trial aimed to test whether anti-CD19 CAR-T cells could safely and effectively treat children with refractory ANCA-associated vasculitis, a rare autoimmune disease. The study was withdrawn before enrolling any participants, so no results are available. It was designed for ch…

This early-stage trial is testing a new treatment called KITE-363 for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard treatments. KITE-363 is a type of cell therapy where a patient's own immune cells are modified in a lab to t…

This phase 3 trial tests whether the drug atrasentan can slow kidney function loss in people with IgA nephropathy, a disease that can lead to kidney failure. About 404 participants receive either atrasentan or a placebo, along with standard care. The main goal is to see if atrase…

This early-phase trial is testing a new treatment called YTB323, a type of CAR T-cell therapy, in 21 adults with severe lupus that hasn't improved with standard treatments. The goal is to see if a single infusion is safe and can control the disease. Researchers will also measure …

This study tests whether the drug zanubrutinib can help people with primary membranous nephropathy, a kidney disease that causes protein leakage. About 178 participants will receive either zanubrutinib or the standard drug tacrolimus. The goal is to see if zanubrutinib reduces pr…

This phase 2 study tests the drug atrasentan in 103 adults with various kidney diseases that cause protein leakage, including IgA nephropathy and FSGS. Participants take a daily tablet to see if it reduces protein in urine, a sign of kidney damage. The goal is to find a new way t…

This study tests a new medicine, NS-229, in 45 adults with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA), which causes inflammation in blood vessels. The goal is to see if NS-229 can help patients achieve remission while lowering their daily steroid d…

This phase 3 trial tests whether adding ianalumab (a biologic injection) to standard therapy helps control active lupus nephritis, a serious kidney complication of lupus. About 452 adults with active lupus nephritis are receiving either ianalumab every 4 or 12 weeks or a placebo,…

This phase 3 trial tests whether the drug povetacicept can reduce protein in the urine and preserve kidney function in adults with IgA nephropathy, a kidney disease. About 605 participants will receive either the drug or a placebo by injection. The study is active but not recruit…

This study tests a drug called obinutuzumab for people with lupus nephritis, a kidney disease caused by lupus. About 271 participants receive either the drug or a placebo, added to their usual treatment. The goal is to see if the drug helps achieve complete kidney response, meani…

This study tests whether a lower dose of the steroid prednisone can treat relapses of nephrotic syndrome in children as effectively as the standard dose. Fifty children aged 1 to 18 with active relapses will be randomly assigned to either the reduced-dose or standard-dose regimen…

This study tests whether a newer drug, benralizumab, works as well as the current standard, mepolizumab, for people with a rare disease called EGPA that inflames blood vessels. About 140 adults with active EGPA will receive either drug for a year, along with their usual steroids.…

This study looks at the long-term safety of a drug called sibeprenlimab for people with IgA nephropathy, a kidney disease. About 600 adults who completed earlier trials of this drug will continue receiving it for up to 2 more years. Researchers will track side effects and measure…

This study tests a drug called tezepelumab in 42 adults with EGPA, a rare disease that causes inflammation in blood vessels and can damage organs. The goal is to see if the drug helps patients reach remission, meaning no active disease and low steroid use. Participants receive ei…

This Phase 3 trial tests sparsentan, a new drug, against irbesartan (a standard treatment) in 406 adults with IgA nephropathy, a kidney disease. The goal is to see if sparsentan better protects kidney function over about 2 years. Participants must have significant protein in thei…

This study offers girls from birth to age 17 the chance to freeze their ovarian tissue before medical treatments that could harm their fertility, such as chemotherapy or radiation. The tissue is removed surgically and stored. Later, if they want to have children, the tissue can b…

This study tests a drug called atacicept given once a month to people with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if monthly dosing lowers harmful antibodies and reduces protein in the urine, which are signs of kidney damage. About 9…

This study tests a drug called obinutuzumab against a standard treatment (tacrolimus) in 142 adults with primary membranous nephropathy, a kidney disease that lets protein leak into urine. The goal is to see if obinutuzumab can bring about complete remission (no protein in urine)…

This study tests the long-term safety and effectiveness of pegcetacoplan in 100 people with two rare kidney diseases, C3 glomerulopathy and IC-MPGN. Participants previously completed a one-year trial and saw benefit from the drug. The goal is to see if pegcetacoplan can keep redu…

This phase 3 study tests BION-1301 (Zigakibart) in 383 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants receive either the drug or a placebo as a shot every 2 weeks for 2 years. The main goal is to see if the drug helps preserve kidney f…

This study looks at whether people with ANCA vasculitis who have reached end-stage kidney disease can safely stop taking immunosuppressive medications. The goal is to see if stopping these drugs lowers the risk of serious infections and other side effects without causing dangerou…

This early-phase study tests a new treatment called Prula-cel for people with autoimmune diseases like lupus, scleroderma, and vasculitis. Prula-cel uses donor immune cells engineered to target and destroy faulty immune cells that attack the body. The goal is to find a safe dose …

This study tests whether a daily dose of alpha lipoic acid, an antioxidant supplement, can lower the risk of heart problems in 50 children who are on regular hemodialysis. Participants will either take the supplement or a placebo pill for a period, and researchers will monitor fo…

This was a planned phase 2 study testing nipocalimab, an experimental drug, in adults with active lupus nephritis (kidney inflammation caused by lupus). The trial aimed to see if adding nipocalimab to standard treatment could improve kidney function. However, the study was withdr…

This phase 3 study tests anifrolumab, an IV drug, against placebo in 359 adults with active lupus nephritis (kidney inflammation from lupus). The main goal is to see if more patients achieve complete kidney response, meaning better kidney function and less protein in urine. The t…

This early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…

This early-phase trial is testing a CAR-T cell therapy called RD06-04 in 12 people with active autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves reprogramming a patient's own immune cells to target and destroy faulty B cells. The main goal is to …

This early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies.…

This early-stage study is testing a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't improved with standard therapies. CNTY-101 uses specially engineered immune cells to target and destroy f…

This early-stage study tests a drug called felzartamab in 14 people with active lupus nephritis, a kidney condition caused by lupus. The drug is a lab-made antibody designed to lower harmful antibody buildup in the kidneys. The main goal is to check safety and how the drug works …

This study tests a drug called telitacicept in 318 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants are at high risk of worsening despite standard blood pressure medications. The goal is to see if telitacicept can reduce protein in the u…

This early-stage study tests a new treatment called AB-101 for people with lupus nephritis or other hard-to-treat lupus. AB-101 uses donated natural killer cells to boost the body's ability to fight the disease. The study aims to see if this approach is safe and can help patients…

This was a planned study to compare a newer drug, obinutuzumab, against a standard treatment (steroids plus cyclophosphamide) for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The goal was to see which treatment worked better and had fe…

This early-stage study tests a therapy called SC291, made from donor immune cells, in 7 people with severe lupus or vasculitis that hasn't improved with standard treatments. The goal is to see if it is safe and tolerable, and to get a first look at whether it can control the dise…

This study tests a new drug, zuberitamab, in 135 adults with primary membranous nephropathy, a kidney condition that causes protein leakage. Participants receive either zuberitamab (two doses two weeks apart) or the standard drug cyclosporine. The main goal is to see if zuberitam…

This study tests whether a drug called mepolizumab can help people with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA) reach remission better than standard treatments. About 100 adults with active EGPA will receive either mepolizumab or usual care, and…

This program provides early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that can lead to kidney failure. Participants must have active disease with significant protein in their urine. The goal is to offer a …

This early-stage trial is testing a new treatment for people with severe lupus or scleroderma that hasn't responded to standard therapies. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty immune cells, and giving them back al…

This early-phase trial is testing a personalized cell therapy called KYV-101 for people with lupus nephritis that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. Only 2 p…

This early-phase trial is testing a new treatment called KYV-101, which uses a patient's own modified immune cells (CAR-T cells) to target and destroy faulty B cells that drive lupus kidney inflammation. The study involves 6 adults with lupus nephritis that hasn't responded to st…

This study tests a new drug called povetacicept in adults with certain autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The goal is to see if the drug is safe and can help control the disease. Participants receive the drug every 4 weeks for at least 6 mo…

This study tests whether dapagliflozin, a drug used in adults for diabetes and kidney protection, can reduce protein leakage in the urine of children with chronic kidney disease. Ten children aged 4 to 18 with persistent proteinuria despite standard therapy will take the drug, an…

This phase 3 trial tests atacicept, a weekly injection, in 376 adults with IgA nephropathy (Berger's disease). The goal is to reduce protein in the urine and slow the loss of kidney function. Participants receive either atacicept or a placebo for about a year. The study is active…

This early-stage study aimed to test a single infusion of CB-010, a CRISPR-edited CAR-T cell therapy made from donor cells, in people with severe lupus that did not respond to standard treatments. The trial was withdrawn before enrolling any participants, so no results are availa…

This study tests a new PET/CT imaging method that uses a special dye to spot kidney scarring (fibrosis) in people with chronic kidney disease. The goal is to see if this scan can accurately measure fibrosis without needing a needle biopsy. 150 patients will be scanned, and the re…

This study tests the Shingrix vaccine in over 2,000 adults with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. Researchers will compare vaccinated patients to unvaccinated ones to see if the vaccine is safe and triggers a s…

This study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…

This study aims to find the genetic causes of kidney diseases like FSGS and nephrotic syndrome. Researchers will collect saliva and urine samples from up to 2,050 participants, including patients and their family members, as well as healthy volunteers. The goal is to understand w…

This study aims to develop better lab tests to diagnose and monitor two rare kidney diseases: atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G). Researchers will analyze blood, cells, and kidney tissue from 180 patients and healthy volunteers to find markers t…

This study aims to find biological markers in blood, saliva, and sputum that can predict how well patients with EGPA (a rare inflammatory disease) and severe asthma respond to the drug mepolizumab. Researchers will analyze proteins in these samples before and after treatment to u…

This study looks at how the antibiotic TMP-SMX changes the bacteria and fungi living in the noses of people with granulomatosis with polyangiitis (GPA), a rare autoimmune disease. Researchers want to understand why this antibiotic helps prevent disease flare-ups. Eight adults wit…

This observational study compares two common blood tests—creatinine and cystatin C—to see which one better estimates actual kidney function in people with nephrotic syndrome. Researchers will use stored blood samples from 50 participants in three ongoing clinical trials. The goal…

This study gathers MRI, CT, and ultrasound images from 300 adults—some healthy, some with kidney or brain disease—to build a collection for future not-for-profit research. No new treatments are being tested; the goal is to make medical images available to scientists for advancing…

This study follows over 3,000 Black people with HIV in the UK to understand how genes and lifestyle affect their risk for kidney disease, heart disease, diabetes, and obesity. Researchers collect health data and blood/urine samples to find genetic markers that predict these condi…